Articles related to PRODUCT RECALL

Manufacturing violations at an Indian facility have triggered a recall of 15 million OTC pain patches, raising concerns about product quality and patient safety across multiple widely-used brands.

The expansion of this recall highlights the critical importance of verifying medication packaging against blister strip labeling, particularly for controlled substances where precise dosing is essential.

The FDA-designated Class II recall affects specific duloxetine lots where exposure may lead to “temporary or medically reversible health consequences or where the probability of serious adverse health consequences is remote.”

The recall of Snapchill coffee products due to potential botulinum toxin contamination highlights the importance of recognizing botulism symptoms and ensuring food safety compliance to prevent serious health risks.

The FDA has withdrawn approval for infigratinib in advanced cholangiocarcinoma following Helsinn Healthcare SA’s request, citing recruitment difficulties for a confirmatory trial.

The FDA has recalled Abbott’s HeartMate 3 LVAD after reports of severe complications during implantation, including blood leakage and air entry, which can lead to serious surgical risks.